Get the Stockscreener App
2.14
1.90%
0.04
After Hours:
2.14
Iovance Biotherapeutics Inc stock is traded at $2.14, with a volume of 8.09M.
It is up +1.90% in the last 24 hours and down -5.73% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.10
Open:
$2.145
24h Volume:
8.09M
Relative Volume:
0.55
Market Cap:
$774.37M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.7398
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
-3.17%
1M Performance:
-5.73%
6M Performance:
-35.15%
1Y Performance:
-78.03%
1-Day Range:
$2.09
$2.16
1-Week Range:
$2.04
$2.34
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.14 | 759.89M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Identifying reversal signals in Iovance Biotherapeutics Inc.Treasury Yields & Fast Gaining Stock Reports - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfolios2025 Volume Leaders & Community Consensus Trade Signals - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Iovance Biotherapeutics Inc. stock prediction for this weekEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Why Iovance Biotherapeutics Inc. stock is favored by top institutionsQuarterly Profit Report & Daily Growth Stock Tips - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - AOL.com
Signal strength of Iovance Biotherapeutics Inc. stock in tech scannersInsider Selling & Smart Allocation Stock Tips - newser.com
Using R and stats models for Iovance Biotherapeutics Inc. forecastingJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play (IOVA) - Seeking Alpha
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockGap Up & High Yield Stock Recommendations - newser.com
Using flow based indicators on Iovance Biotherapeutics Inc.July 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
Real time breakdown of Iovance Biotherapeutics Inc. stock performanceJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potential - newser.com
Iovance Biotherapeutics (NASDAQ:IOVA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraMarket Sentiment Summary & Daily Chart Pattern Signal Reports - newser.com
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat
Iovance Biotherapeutics Inc Stock Analysis and ForecastIndustrial Stocks Review & Stay Ahead With Daily Market Discussions - earlytimes.in
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance
Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com
Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm
How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com
Analyzing Iovance Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Volatility clustering patterns for Iovance Biotherapeutics Inc.Quarterly Market Review & Capital Efficiency Focused Strategies - newser.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):